CN101765608B - 新白蛋白结合组合物、方法及应用 - Google Patents

新白蛋白结合组合物、方法及应用 Download PDF

Info

Publication number
CN101765608B
CN101765608B CN200880101168.4A CN200880101168A CN101765608B CN 101765608 B CN101765608 B CN 101765608B CN 200880101168 A CN200880101168 A CN 200880101168A CN 101765608 B CN101765608 B CN 101765608B
Authority
CN
China
Prior art keywords
albumin
polypeptide
fusion rotein
seq
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880101168.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101765608A (zh
Inventor
L·阿布拉姆森
A·荣森
J·多甘
P-A·尼格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of CN101765608A publication Critical patent/CN101765608A/zh
Application granted granted Critical
Publication of CN101765608B publication Critical patent/CN101765608B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880101168.4A 2007-07-31 2008-07-17 新白蛋白结合组合物、方法及应用 Active CN101765608B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
US60/962,618 2007-07-31
EP07113533.9 2007-07-31
EP07113533 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510071238.8A Division CN104710518A (zh) 2007-07-31 2008-07-17 新白蛋白结合组合物、方法及应用

Publications (2)

Publication Number Publication Date
CN101765608A CN101765608A (zh) 2010-06-30
CN101765608B true CN101765608B (zh) 2015-03-11

Family

ID=40057660

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880101168.4A Active CN101765608B (zh) 2007-07-31 2008-07-17 新白蛋白结合组合物、方法及应用
CN201510071238.8A Pending CN104710518A (zh) 2007-07-31 2008-07-17 新白蛋白结合组合物、方法及应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510071238.8A Pending CN104710518A (zh) 2007-07-31 2008-07-17 新白蛋白结合组合物、方法及应用

Country Status (11)

Country Link
US (2) US8937153B2 (cg-RX-API-DMAC7.html)
EP (2) EP2190863B1 (cg-RX-API-DMAC7.html)
JP (1) JP5718638B2 (cg-RX-API-DMAC7.html)
CN (2) CN101765608B (cg-RX-API-DMAC7.html)
AU (1) AU2008281913B2 (cg-RX-API-DMAC7.html)
CA (1) CA2694139C (cg-RX-API-DMAC7.html)
DE (1) DE08786222T1 (cg-RX-API-DMAC7.html)
DK (1) DK2190863T3 (cg-RX-API-DMAC7.html)
ES (1) ES2346178T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211040A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009016043A2 (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2346178T3 (es) * 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
DK2977088T3 (en) * 2010-03-08 2017-10-09 Ge Healthcare Bioprocess R&D Ab IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE
KR20130093470A (ko) * 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
MX2013000314A (es) * 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
SG187682A1 (en) * 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
EP2643348B1 (en) 2010-11-26 2025-02-12 Molecular Partners AG Improved capping modules for designed ankyrin repeat proteins
MX347818B (es) * 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
EP2729481B1 (en) * 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2729160B1 (en) * 2011-07-08 2019-03-27 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
ES2715638T3 (es) 2012-02-20 2019-06-05 Swedish Orphan Biovitrum Ab Publ Polipéptidos que se unen al complemento humano C5
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
EP2830665A1 (en) * 2012-03-28 2015-02-04 Affibody AB Oral administration
WO2013177398A2 (en) 2012-05-25 2013-11-28 Janssen Biotech, Inc. Non-natural consensus albumin binding domains
CN111763247B (zh) * 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
CN104768976B (zh) 2012-10-05 2020-09-22 阿菲博迪公司 Her3结合多肽
CN104854127B (zh) * 2012-10-25 2020-12-25 阿菲博迪公司 白蛋白结合多肽
JP6396303B2 (ja) * 2012-10-25 2018-09-26 アフィボディ・アーベー アルブミン結合を含有するタンパク質の分離方法
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
JP6619650B2 (ja) 2013-03-14 2019-12-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 新規のｐｃｓｋ９結合タンパク質
HK1218534A1 (zh) 2013-03-14 2017-02-24 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
KR102191654B1 (ko) 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
BR112015026122A8 (pt) 2013-04-18 2020-01-21 Armo Biosciences Inc agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
SMT202100006T1 (it) 2013-08-28 2021-03-15 Ipc Research Llc Polipeptidi stabili che si legano al complemento umano c5
EP3039033B1 (en) 2013-08-28 2019-06-19 Affibody AB Binding polypeptides having a mutated scaffold
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2014346537A1 (en) 2013-11-11 2016-05-19 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MY192917A (en) 2014-07-30 2022-09-15 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
ES2744588T3 (es) 2014-09-17 2020-02-25 Affibody Ab Nuevos polipéptidos
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6722175B2 (ja) 2014-10-31 2020-07-15 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を処置するための組成物及びその使用方法
AU2016208161B2 (en) 2015-01-12 2020-01-16 Affibody Ab IL-17A-binding polypeptides
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
CN111164104A (zh) * 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
WO2019147954A1 (en) * 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
US20210316007A1 (en) * 2018-09-07 2021-10-14 Duke University Nanoparticulate drug delivery systems
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2020245171A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
CA3150442A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CA3200702A1 (en) 2020-12-21 2022-06-30 Affibody Ab New polypeptide
US20240124533A1 (en) 2021-02-15 2024-04-18 Affibody Ab New her2-binding polypeptide
KR20240139058A (ko) 2022-02-08 2024-09-20 애피바디 에이비 흉선 기질 림포포이에틴에 결합하는 단백질 z 변이체 및 이의 의학적 용도
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
CN119677787A (zh) 2022-08-10 2025-03-21 兴和株式会社 亲和体微胞药物复合体
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드
WO2024227930A1 (en) 2023-05-04 2024-11-07 Affibody Ab New polypeptide
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025158010A1 (en) 2024-01-25 2025-07-31 Affibody Ab Her2-binding polypeptide
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056464A2 (en) * 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
AU2001298053A1 (en) * 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US8642743B2 (en) * 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
ES2346178T3 (es) * 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056464A2 (en) * 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yanan He et al..An artificiallly evolved binding module facilitates chemical shift epitope mapping of GA domain interactions with phylogeetically diverse albumins.《Protein Science》.2007,(第16期),1490-1494. *

Also Published As

Publication number Publication date
JP5718638B2 (ja) 2015-05-13
EP2546261A3 (en) 2013-08-14
EP2190863B1 (en) 2015-09-02
US20150158916A1 (en) 2015-06-11
HK1211040A1 (en) 2016-05-13
US10118949B2 (en) 2018-11-06
EP2546261A2 (en) 2013-01-16
JP2010534486A (ja) 2010-11-11
WO2009016043A3 (en) 2009-06-04
CN101765608A (zh) 2010-06-30
CN104710518A (zh) 2015-06-17
CA2694139A1 (en) 2009-02-05
US8937153B2 (en) 2015-01-20
DK2190863T3 (en) 2015-11-30
AU2008281913B2 (en) 2013-11-07
AU2008281913A1 (en) 2009-02-05
CA2694139C (en) 2018-06-05
US20100273979A1 (en) 2010-10-28
ES2346178T3 (es) 2015-11-02
WO2009016043A2 (en) 2009-02-05
ES2346178T1 (es) 2010-10-13
EP2190863A2 (en) 2010-06-02
DE08786222T1 (de) 2010-11-25

Similar Documents

Publication Publication Date Title
CN101765608B (zh) 新白蛋白结合组合物、方法及应用
CN103459415B (zh) 设计的与血清白蛋白结合的重复蛋白
ES2880336T3 (es) Métodos y productos para la síntesis de proteínas de fusión
CA2710140C (en) Polypeptide libraries with a predetermined scaffold
JP6590695B2 (ja) アルブミン結合ポリペプチド
DK2912054T3 (en) Albumin-binding polypeptide
WO2024084203A1 (en) Single domain antibodies binding to albumin
WO2024074762A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
Järver et al. Chemical synthesis and evaluation of a backbone‐cyclized minimized 2‐helix Z‐domain
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK40012160A (en) Designed repeat proteins binding to serum albumin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant